Artificial Intelligence-Based Electrocardiographic Analysis Facilitated Diagnosis of Hypertrophic Cardiomyopathy With Successful Treatment Using Mavacamten

Figures

• 

  Figure 1. Baseline Electrocardiographic and Echocardiographic Data (A) Baseline electrocardiogram (ECG) at initial outpatient visit. (B) Artificial intelligence analyzed ECG.

• 

  Figure 2. Baseline Echocardiographic Data (A) Parasternal long axis view demonstrating severe basal septal hypertrophy with maximal measurement of 2 cm. (B) Spectral Doppler demonstrating no significant left ventricular outflow tract (LVOT) obstruction of 24 mm Hg at rest. (C) Spectral Doppler demonstrating severe LVOT obstruction of 68 mm Hg following Valsalva maneuver. (D) Spectral Doppler demonstrating severe LVOT obstruction of 72 mm Hg postexercise.

• 

  Figure 3. Echocardiographic Data After 4 Weeks of Mavacamten Treatment (A) Spectral Doppler demonstrating no significant left ventricular outflow tract (LVOT) obstruction of 7 mm Hg at rest. (B) Spectral Doppler demonstrating no significant LVOT obstruction of 28 mm Hg following Valsalva maneuver.

• 

  Figure 4. Echocardiographic Data After 8 Weeks of Mavacamten Treatment (A) Spectral Doppler demonstrating no significant left ventricular outflow tract (LVOT) obstruction of 9 mm Hg at rest. (B) Spectral Doppler demonstrating severe LVOT obstruction of 18 mm Hg following Valsalva maneuver.